Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy

article Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy published yes Carsten Lukas author Barbara Bellenberg author Horst K. Hahn author Jan Rexilius author 2457360000-0002-4579-214X Robert Drescher author Kerstin Hellwig author Odo Köster author Sebastian Schimrigk author SAGE Publications2009 eng Therapeutic Advances in Neurological Disorders 1756-2864 1756-286410.1177/1756285609343480 26349-355 Lukas C, Bellenberg B, Hahn HK, et al. Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. Therapeutic Advances in Neurological Disorders. 2009;2(6):349-355. doi:<a href="https://doi.org/10.1177/1756285609343480">10.1177/1756285609343480</a> Lukas, Carsten, et al. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy.” Therapeutic Advances in Neurological Disorders, vol. 2, no. 6, SAGE Publications, 2009, pp. 349–55, doi:<a href="https://doi.org/10.1177/1756285609343480">10.1177/1756285609343480</a>. C. Lukas, B. Bellenberg, H.K. Hahn, J. Rexilius, R. Drescher, K. Hellwig, O. Köster, S. Schimrigk, Therapeutic Advances in Neurological Disorders 2 (2009) 349–355. Lukas, Carsten, Barbara Bellenberg, Horst K. Hahn, Jan Rexilius, Robert Drescher, Kerstin Hellwig, Odo Köster, and Sebastian Schimrigk. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy.” Therapeutic Advances in Neurological Disorders 2, no. 6 (2009): 349–55. <a href="https://doi.org/10.1177/1756285609343480">https://doi.org/10.1177/1756285609343480</a>. Lukas, C., Bellenberg, B., Hahn, H. K., Rexilius, J., Drescher, R., Hellwig, K., … Schimrigk, S. (2009). Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. Therapeutic Advances in Neurological Disorders, 2(6), 349–355. <a href="https://doi.org/10.1177/1756285609343480">https://doi.org/10.1177/1756285609343480</a> @article{Lukas_Bellenberg_Hahn_Rexilius_Drescher_Hellwig_Köster_Schimrigk_2009, title={Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy}, volume={2}, DOI={<a href="https://doi.org/10.1177/1756285609343480">10.1177/1756285609343480</a>}, number={6}, journal={Therapeutic Advances in Neurological Disorders}, publisher={SAGE Publications}, author={Lukas, Carsten and Bellenberg, Barbara and Hahn, Horst K. and Rexilius, Jan and Drescher, Robert and Hellwig, Kerstin and Köster, Odo and Schimrigk, Sebastian}, year={2009}, pages={349–355} } Lukas, Carsten ; Bellenberg, Barbara ; Hahn, Horst K. ; Rexilius, Jan ; Drescher, Robert ; Hellwig, Kerstin ; Köster, Odo ; Schimrigk, Sebastian: Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. In: Therapeutic Advances in Neurological Disorders Bd. 2, SAGE Publications (2009), Nr. 6, S. 349–355 C. Lukas et al., “Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy,” Therapeutic Advances in Neurological Disorders, vol. 2, no. 6, pp. 349–355, 2009. 66592026-03-02T10:03:31Z2026-03-17T15:29:33Z